Form 10-Q Carisma Therapeutics For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
D. Boral Capital Reiterates Buy Rating on Carisma Therapeutics Inc (CARM)
November 11, 2024 7:13 AM ESTD. Boral Capital analyst Jason Kolbert reiterated a Buy rating and $24.00 price target on Carisma Therapeutics Inc (NASDAQ: CARM).
The analyst comments "We model 0525 in HER2 Breast Cancer (BC). We apply a probability of success factor of just 30% and use a 30%... More
